Quidel Corp
XBER:QL1

Watchlist Manager
Quidel Corp Logo
Quidel Corp
XBER:QL1
Watchlist
Price: 98.5 EUR -1.01% Market Closed
Market Cap: €4.1B

Gross Margin

46.7%
Current
Declining
by 1.8%
vs 3-y average of 48.4%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
46.7%
=
Gross Profit
$1.3B
/
Revenue
$2.7B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
46.7%
=
Gross Profit
€1.3B
/
Revenue
$2.7B

Peer Comparison

Country Company Market Cap Gross
Margin
US
Quidel Corp
NASDAQ:QDEL
1.5B USD
Loading...
US
Medline Inc
NASDAQ:MDLN
63.4B USD
Loading...
JP
Hoya Corp
TSE:7741
9.6T JPY
Loading...
CH
Alcon AG
SIX:ALC
32.9B CHF
Loading...
DK
Coloplast A/S
CSE:COLO B
110.1B DKK
Loading...
US
Align Technology Inc
NASDAQ:ALGN
13.6B USD
Loading...
UK
ConvaTec Group PLC
LSE:CTEC
5B GBP
Loading...
CA
Bausch + Lomb Corp
NYSE:BLCO
6.5B USD
Loading...
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
41.1B CNY
Loading...
JP
Asahi Intecc Co Ltd
TSE:7747
893.1B JPY
Loading...
US
Lantheus Holdings Inc
NASDAQ:LNTH
5B USD
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
54th
Based on 12 729 companies
54th percentile
46.7%
Low
-24 813% — 28.9%
Typical Range
28.9% — 60.5%
High
60.5% — 10 905 714.3%
Distribution Statistics
the United States of America
Min -24 813%
30th Percentile 28.9%
Median 43%
70th Percentile 60.5%
Max 10 905 714.3%

Quidel Corp
Glance View

Quidel Corporation, a player in the diagnostic healthcare industry, has steadily navigated the labyrinth of medical innovation, carving out a niche in rapid diagnostic testing. Born out of a mission to streamline the process of disease detection, Quidel has leveraged biotechnology to develop fast, reliable diagnostic solutions that address widespread health issues. This company’s arsenal includes tests for infectious diseases, reproductive health, and autoimmune disorders—each meticulously designed to expedite the diagnostic process while maintaining a stringent commitment to accuracy. By fostering partnerships with healthcare providers and aligning with technological advancements, Quidel has positioned itself as indispensable in the clinic setting, where swift decision-making can significantly impact patient care. At the heart of Quidel's business model is its focus on providing tangible value to both healthcare professionals and patients. The company generates revenue primarily through the sale of its diagnostic products, which are utilized in settings ranging from small clinics to large hospital networks. Quidel's innovative platforms, like the Sofia and Solana systems, are lauded for their efficiency and ease of use, attributes that resonate particularly well in medical environments under pressure to deliver fast and effective results. By effectively converting scientific expertise into practical and user-friendly applications, Quidel not only enhances patient outcomes but also fortifies its financial standing within the competitive landscape of medical diagnostics.

QL1 Intrinsic Value
230.32 EUR
Undervaluation 57%
Intrinsic Value
Price
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
46.7%
=
Gross Profit
$1.3B
/
Revenue
$2.7B
What is Quidel Corp's current Gross Margin?

The current Gross Margin for Quidel Corp is 46.7%, which is below its 3-year median of 48.4%.

How has Gross Margin changed over time?

Over the last 3 years, Quidel Corp’s Gross Margin has decreased from 59.3% to 46.7%. During this period, it reached a low of 46.2% on Dec 29, 2024 and a high of 59.3% on Jan 1, 2023.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett